Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 125
Filtrar
1.
World J Urol ; 39(12): 4335-4344, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-34216242

RESUMO

OBJECTIVE: To perform an external validation of this RC-pentafecta. METHOD: Between January 2014 and December 2019, 104 consecutive patients who underwent RARC with ICUD within 6 urological centers were analyzed retrospectively. Patients who simultaneously demonstrated negative soft tissue surgical margins (STSMs), a lymph node (LN) yield ≥ 16, absence of major (Clavien-Dindo grade III-V) 90-day postoperative complications, absence of UD-related long-term sequelae, and absence of 12-month clinical recurrence were considered to have achieved RC-pentafecta. A multivariable logistic regression model was used to measure predictors for achieving RC-pentafecta. We analyzed the influence of this RC-pentafecta on survival, and the impact ofthe surgical experience. RESULTS: Since 2014, 104 patients who had completed at least 12 months of follow-up were included. Over a mean follow-up of 18 months, a LN yield ≥ 16, negative STSMs, absence of major complications at 90 days, and absence of UD-related surgical sequelae and clinical recurrence at ≤ 12 months were observed in 56%, 96%, 85%, 81%, and 91% of patients, respectively, resulting in a RC-pentafecta rate of 39.4%. Multivariate analysis showed that age was an independent predictor of pentafecta achievement (odds ratio [OR], 0.96; 95% confidence interval [CI], 0.90. 0.99; p = 0.04). The surgeon experience had an impact on the validation of the criteria. CONCLUSION: This study confirmed that the RC-pentafecta is reproducible and could be externally used for the outcome assessment after RARC with ICUD. Therefore, the RC-pentafecta could be a useful tool to assess surgical success and its impact on different outcomes.


Assuntos
Cistectomia/métodos , Procedimentos Cirúrgicos Robóticos , Neoplasias da Bexiga Urinária/cirurgia , Derivação Urinária/métodos , Idoso , Europa (Continente) , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos
2.
Actas Urol Esp (Engl Ed) ; 45(4): 273-280, 2021 May.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-33541744

RESUMO

INTRODUCTION AND OBJECTIVE: The management of renal tumors ≤ 4 cm in elderly population or patients with comorbidities is a challenge, for which ablative therapies are an interesting alternative. The objective is to evaluate in our center the role of percutaneous radiofrequency in the treatment of small renal masses, the associated complications and the results obtained. MATERIAL AND METHODS: Retrospective evaluation of the radiofrequency treatments carried out between April 2010 and April 2020 in our center. Demographic data, associated comorbidities, tumor characteristics, complications and oncological and functional outcomes were reviewed. RESULTS: Fifty-seven tumors were treated in 53 patients. Mean follow-up of 48.2 months. The percentage of complete ablations obtained was of 89.5%. There were 19.3% of complications. According to Clavien-Dindo and SIR classification systems, 3.5% and 5.3% were major complications. A statistically significant association was found between the initial result of ablation and age (p = 0.047), RENAL-m (p = 0.044), the presence of cystic component (p = 0.049) and tumor size (p = 0.01). The cut-off point for size was established at 25 mm (p = 0.012). In multivariate analysis, only size remained as a predictor of initial ablation result (p = 0.01; OR 1.183; CI 95% 1.041-1.345). Cancer-specific survival and 5-year recurrence-free survival were 98.1% and 89.5%, respectively. A mean decrease of MDRD-4 of 6.59 mL/min (p = 0.005) was observed in the first six months after RFA. CONCLUSIONS: Given the excellent oncological and functional results demonstrated, ultrasound-guided percutaneous radiofrequency ablation is an effective and safe treatment for small renal masses in selected patients.


Assuntos
Ablação por Cateter , Neoplasias Renais , Idoso , Humanos , Neoplasias Renais/cirurgia , Estudos Retrospectivos , Resultado do Tratamento , Ultrassonografia
3.
J Biol Regul Homeost Agents ; 32(2): 407-413, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29685026

RESUMO

Articular pain is one of the most frequent complaints practitioners face in their daily work. With an aging population, many patients have multiple comorbidities that are associated with the presence of chronic diseases, while others experience allergies, side effects or do not respond to standard medications or procedures. Therefore, there is an urgent need for new effective and safe strategies to manage articular pain, especially in its chronic manifestations. This randomized controlled trial was designed to assess the efficacy of a single therapy session using a biophysical procedure matched with a common non-steroidal anti-inflammatory drug (ibuprofen) and placebo. Biophysical therapy was performed using a Med Select 729 device. One hundred fifty patients (mean age 56±15.6 years) diagnosed with acute or chronic articular pain at different locations were randomized into 3 groups and the Numeric Pain Rating Score (NPRS) was used to measure pain at baseline, after one week, one month, and three months. While no difference in NPRS was observed at baseline among the 3 groups, a statistically significant difference was observed at all subsequent time points, respectively, after one week (p less than 0.05), one month (p less than 0.001), and three months (p less than 0.01), for both ibuprofen and biophysical groups vs placebo. Biophysical treatment of articular pain was shown to be as effective as a conventional non-steroidal anti-inflammatory treatment over a period of 3 months compared to placebo and could, therefore, represent an integrative, safe and long-lasting therapy to be considered for the management of acute and particularly chronic articular pain in current medical practice.


Assuntos
Analgésicos não Narcóticos/uso terapêutico , Artralgia/terapia , Terapia por Estimulação Elétrica/métodos , Ibuprofeno/uso terapêutico , Adulto , Idoso , Anti-Inflamatórios não Esteroides/uso terapêutico , Método Duplo-Cego , Radiação Eletromagnética , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
4.
Am J Gastroenterol ; 113(2): 265-272, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-28809388

RESUMO

OBJECTIVES: Few data are available to describe the changes in incidence of pediatric-onset inflammatory bowel disease (IBD). The aim of this study was to describe changes in incidence and phenotypic presentation of pediatric-onset IBD in northern France during a 24-year period. METHODS: Pediatric-onset IBD (<17 years) was issued from a population-based IBD study in France between 1988 and 2011. Age groups and digestive location were defined according to the Paris classification. RESULTS: 1,350 incident cases were recorded (8.3% of all IBD) including 990 Crohn's disease (CD), 326 ulcerative colitis (UC) and 34 IBD unclassified (IBDU). Median age at diagnosis was similar in CD (14.4 years (Q1=11.8-Q3=16.0)) and UC (14.0 years (11.0-16.0)) and did not change over time. There were significantly more males with CD (females/males=0.82) than UC (females/males=1.25) (P=0.0042). Median time between onset of symptoms and IBD diagnosis was consistently 3 months (1-6). Mean incidence was 4.4/105 for IBD overall (3.2 for CD, 1.1 for UC and 0.1 for IBDU). From 1988-1990 to 2009-2011, a dramatic increase in incidences of both CD and UC were observed in adolescents (10-16 years): for CD from 4.2 to 9.5/105 (+126%; P<0.001) and for UC, from 1.6 to 4.1/105 (+156%; P<0.001). No modification in age or location at diagnosis was observed in either CD or UC. CONCLUSIONS: In this population-based study, CD and UC incidences increased dramatically in adolescents across a 24-year span, suggesting that one or more strong environmental factors may predispose this population to IBD.


Assuntos
Colite Ulcerativa/epidemiologia , Doença de Crohn/epidemiologia , Adolescente , Criança , Feminino , França/epidemiologia , Humanos , Incidência , Doenças Inflamatórias Intestinais/epidemiologia , Masculino
5.
Int J Pharm ; 505(1-2): 52-60, 2016 May 30.
Artigo em Inglês | MEDLINE | ID: mdl-27041126

RESUMO

Oil depots are parenteral drug formulations meant for sustained release of lipophilic compounds. According to mass transport models, the drug-release rate from these injections is determined by the surface area of the oil depot. Until now, the size of the surface area of injected depots has not been assessed, however. MRI provides an excellent possibility to distinguish between water and adipose tissue. The aim of this study was to investigate whether MRI can be used to determine the shape and hence the surface area of oil depots in muscle tissue. The developed MRI-scan protocol is demonstrated to be suitable for visualising oil depots. It was applied to determine the surface area of 0.5mL oil, i.m. injected in healthy volunteers. The mean (±RSD) surface area and volume of the depots recovered after injection was 755.4mm(2) (±26.5) and 520.1mm(3) (±24.6). It is shown that the depot disappearance from the injection site is very variable between volunteers. It is suggested that the oil is first solubilized and subsequently distributed. In all cases, the oil was not detectable after 14days. These factors are relevant for the understanding of the mechanism by which compounds are released out of oil depots.


Assuntos
Tecido Adiposo/metabolismo , Imageamento por Ressonância Magnética/métodos , Músculos/metabolismo , Óleo de Gergelim/administração & dosagem , Adulto , Animais , Preparações de Ação Retardada , Humanos , Injeções Intramusculares , Masculino , Pessoa de Meia-Idade , Óleo de Gergelim/química , Óleo de Gergelim/farmacocinética , Suínos , Fatores de Tempo , Distribuição Tecidual , Água/química
6.
Acta Neurol Scand ; 126(2): 77-97, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22428782

RESUMO

Fabry disease is a multisystem, X-linked, lysosomal storage disorder caused by a mutation in the GLA gene on chromosome Xq22 resulting in alpha-galactosidase A enzyme (α-Gal A) deficiency. Neurological manifestations other than cerebrovascular accidents include small fibre neuropathy and dysautonomic disorders, which may be the presenting clinical features in a proportion of patients. An atypical disease onset may be misdiagnosed until the emergence of a more typical clinical picture, characterized by chronic renal and cardiac failure. Thus, neurologists should consider Fabry disease in differential diagnosis and provide an appropriate diagnostic work up. This review focuses on central and peripheral nervous system involving available diagnostic tools and diagnostic work up in Fabry disease. It also covers the most recent evidence regarding enzyme replacement therapy.


Assuntos
Terapia de Reposição de Enzimas , Doença de Fabry/tratamento farmacológico , Doença de Fabry/fisiopatologia , alfa-Galactosidase/uso terapêutico , Transtornos Cerebrovasculares/diagnóstico , Transtornos Cerebrovasculares/etiologia , Diagnóstico Diferencial , Doença de Fabry/diagnóstico , Humanos , Doenças do Sistema Nervoso Periférico/diagnóstico , Doenças do Sistema Nervoso Periférico/etiologia
7.
J Cell Mol Med ; 15(8): 1645-87, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-20015202

RESUMO

Data from pre-clinical and clinical studies provide evidence that colony-stimulating factors (CSFs) and other growth factors (GFs) can improve stroke outcome by reducing stroke damage through their anti-apoptotic and anti-inflammatory effects, and by promoting angiogenesis and neurogenesis. This review provides a critical and up-to-date literature review on CSF use in stroke. We searched for experimental and clinical studies on haemopoietic GFs such as granulocyte CSF, erythropoietin, granulocyte-macrophage colony-stimulating factor, stem cell factor (SCF), vascular endothelial GF, stromal cell-derived factor-1α and SCF in ischemic stroke. We also considered studies on insulin-like growth factor-1 and neurotrophins. Despite promising results from animal models, the lack of data in human beings hampers efficacy assessments of GFs on stroke outcome. We provide a comprehensive and critical view of the present knowledge about GFs and stroke, and an overview of ongoing and future prospects.


Assuntos
Isquemia Encefálica/tratamento farmacológico , Encéfalo/efeitos dos fármacos , Peptídeos e Proteínas de Sinalização Intercelular/farmacologia , Acidente Vascular Cerebral/tratamento farmacológico , Animais , Encéfalo/irrigação sanguínea , Encéfalo/patologia , Isquemia Encefálica/complicações , Fator Estimulador de Colônias de Granulócitos/farmacologia , Fator Estimulador de Colônias de Granulócitos e Macrófagos/farmacologia , Humanos , Camundongos , Ratos , Acidente Vascular Cerebral/etiologia
8.
Eur J Clin Microbiol Infect Dis ; 29(11): 1435-41, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-20734098

RESUMO

The purpose of this investigation was to assess the usefulness of mycobacteremia detection in human immunodeficiency virus (HIV) patients with suspected tuberculosis. The study included 47 patients with suspected tuberculosis and confirmed HIV infection. A first blood sample was incubated in a BACTEC 9050 MB system, while white blood cells isolation was performed on a second blood specimen before incubation in a BACTEC MGIT 960 system. The third specimen was taken from the affected organs of each patient according to their clinical profile. Twelve (25.5%) patients were positive for mycobacterial infection identified by any of the methods used. Ten (21.2%) were positive for Mycobacterium tuberculosis and 2 (4.3%) for M. avium. Six patients were diagnosed by the culture of specimen from affected organs only, whilst three other patients were positive exclusively for blood cultures. Three additional patients were diagnosed by both methods. Four patients with negative cultures were ultimately diagnosed with tuberculosis by measuring the adenosine deaminase levels. Mycobacteremia detection can be used to increase the sensitivity of the diagnosis of tuberculosis and other mycobacteria in patients with HIV. However, it cannot be used as the sole diagnostic method. Clinical specimen cultures do not provide 100% diagnostic accuracy and it is, therefore, critical to further improve the mycobacteria detection sensitivity.


Assuntos
Técnicas Bacteriológicas , Infecções por HIV/complicações , Complexo Mycobacterium avium/isolamento & purificação , Infecção por Mycobacterium avium-intracellulare/diagnóstico , Mycobacterium tuberculosis/isolamento & purificação , Tuberculose/complicações , Tuberculose/diagnóstico , Adenosina Desaminase/metabolismo , Bacteriemia/diagnóstico , Bacteriemia/microbiologia , Humanos , Infecção por Mycobacterium avium-intracellulare/complicações , Infecção por Mycobacterium avium-intracellulare/microbiologia , Sensibilidade e Especificidade , Tuberculose/microbiologia
9.
Rev. colomb. enferm ; 5(5): 41-52, ago. 2010. tab
Artigo em Espanhol | LILACS, BDENF - Enfermagem | ID: lil-616048

RESUMO

Se realizó un estudio cualitativo basado en experiencias y percepciones de 8 madres de niñas y niños con cáncer, entre los 26 y 38 años, que son las principales cuidadoras de sus hijos(as), mediante entrevistas a profundidad. Este estudio se realizó en Bogotá, en el Servicio de Oncología Pediátrica del Hospital Militar Central (HMC), con el fin de conocer las necesidades prioritarias que surgen de sus vivencias como cuidadoras. Se estableció que, además de enfrentarse con una experiencia altamente compleja relativa a la salud de sus hijos(as), han debido asumir cambios trascendentales en su estilo de vida y han tenido que desarrollar habilidades para su cuidado en casa. Se identifican, entre los cambios fundamentales que han surgido en sus vidas, el traslado de su lugar de vivienda —lo cual limita además su posibilidad de contar con redes de apoyo— el dejar a un lado su vida laboral y el tener que asumir actividades de cuidado prácticamente permanentes, dadas las condiciones de salud de sus hijas(os). La expresión de sus sentimientos es una necesidad que posponende manera permanente; su rutina diaria no da lugar a su desarrollo personal, siendo sus condiciones psicosociales, además del fortalecimiento de competencias para el cuidado de sus niños(as), prioridades a tenerse en cuenta en acciones a favor de este grupo. Se recomienda generar grupos de apoyo entre ellas así como realizar talleres en que se contemplen sus necesidades y calidad de vida.


Assuntos
Estudos de Avaliação como Assunto , Qualidade de Vida , Comportamento Materno , Cuidado da Criança , Neoplasias , Criança , Saúde da Criança , Serviços de Saúde da Criança , Colômbia
10.
J Neurol Sci ; 284(1-2): 113-5, 2009 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-19428025

RESUMO

A number of mutations were described in the TTR gene. They were generally related to a variety of inherited syndromes named 'familial TTR-related amyloidoses'. Although TTR mutations were mostly associated with familial amyloid polyneuropathy (FAP), these molecular variants were also found in patients with recurrent stroke, subarachnoidal bleeding and radiological findings of cerebral, cerebellar, cortical-subcortical infarctions and hemosiderosis. We describe a 46 y.o. man with recurrent cerebral haemorrhages carrying Asn90His variant of TTR gene. This mutation has been reported both in FAP and asymptomatic subjects raising the doubt on the possible amyloidogenetic role of this variant. The absence of mutation in the patient's father, who had a history of unexplained cerebral haemorrhage and the lack of symptoms and sign of cerebral bleeding in the two patient's sisters, carrying the same mutation, seem to support the hypothesis that His90Asn TTR mutation do not have an impact in amyloid formation. It has still to be established whether other gene variants in our patient could act synergistically with His90Asn TTR mutation in increasing the risk of CNS haemorrhages.


Assuntos
Neuropatias Amiloides Familiares/genética , Hemorragia Cerebral/genética , Mutação de Sentido Incorreto , Mutação Puntual , Pré-Albumina/genética , Adulto , Substituição de Aminoácidos , Isquemia Encefálica/genética , Análise Mutacional de DNA , Éxons/genética , Saúde da Família , Feminino , Predisposição Genética para Doença , Humanos , Hemorragias Intracranianas/genética , Masculino , Pessoa de Meia-Idade , Pré-Albumina/fisiologia , Recidiva
11.
Am J Physiol Lung Cell Mol Physiol ; 295(4): L552-65, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18658273

RESUMO

Nanomaterials are frontier technological products used in different manufactured goods. Because of their unique physicochemical, electrical, mechanical, and thermal properties, single-walled carbon nanotubes (SWCNT) are finding numerous applications in electronics, aerospace devices, computers, and chemical, polymer, and pharmaceutical industries. SWCNT are relatively recently discovered members of the carbon allotropes that are similar in structure to fullerenes and graphite. Previously, we (47) have reported that pharyngeal aspiration of purified SWCNT by C57BL/6 mice caused dose-dependent granulomatous pneumonia, oxidative stress, acute inflammatory/cytokine responses, fibrosis, and decrease in pulmonary function. To avoid potential artifactual effects due to instillation/agglomeration associated with SWCNT, we conducted inhalation exposures using stable and uniform SWCNT dispersions obtained by a newly developed aerosolization technique (2). The inhalation of nonpurified SWCNT (iron content of 17.7% by weight) at 5 mg/m(3), 5 h/day for 4 days was compared with pharyngeal aspiration of varying doses (5-20 microg per mouse) of the same SWCNT. The chain of pathological events in both exposure routes was realized through synergized interactions of early inflammatory response and oxidative stress culminating in the development of multifocal granulomatous pneumonia and interstitial fibrosis. SWCNT inhalation was more effective than aspiration in causing inflammatory response, oxidative stress, collagen deposition, and fibrosis as well as mutations of K-ras gene locus in the lung of C57BL/6 mice.


Assuntos
Administração por Inalação , Inflamação/etiologia , Pulmão/efeitos dos fármacos , Mutagênese , Nanotubos de Carbono/efeitos adversos , Estresse Oxidativo/efeitos dos fármacos , Transtornos Respiratórios/induzido quimicamente , Aerossóis/administração & dosagem , Animais , Carbono/farmacologia , Feminino , Fibrose , Inflamação/patologia , Pulmão/patologia , Camundongos , Camundongos Endogâmicos C57BL , Faringe
12.
Pediatr Transplant ; 11(4): 436-40, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17493227

RESUMO

Kidney transplantation (KT) in children with end-stage renal disease and an abnormal bladder poses a complex management challenge. Ureterocystoplasty (UC) has been previously reported in older children with non-compliant bladders, but the timing and technique of repair are controversial. This case reports the youngest patient, a 20-month-old boy to undergo successful single-stage UC and living-related KT. UC was performed because of a fibrotic, non-compliant bladder. A temporary vesicostomy was placed to provide adequate drainage in the presence of urethral stenosis. The patient developed a single episode of pyelonephritis within the first six months post-operatively, but there were no other urologic complications. At 13 months, the renal function is excellent with a mean glomerular filtration rate of 100 mL/min/1.73 m(2) and no clinical evidence of rejection. This case demonstrates that simultaneous UC and KT can be safely performed even in infants with non-compliant bladders and renal failure.


Assuntos
Falência Renal Crônica/cirurgia , Transplante de Rim/métodos , Procedimentos de Cirurgia Plástica/métodos , Ureter/cirurgia , Doenças da Bexiga Urinária/cirurgia , Bexiga Urinária/anormalidades , Procedimentos Cirúrgicos Urológicos/métodos , Fibrose/congênito , Fibrose/diagnóstico , Fibrose/cirurgia , Seguimentos , Humanos , Lactente , Falência Renal Crônica/complicações , Masculino , Ureter/diagnóstico por imagem , Bexiga Urinária/diagnóstico por imagem , Bexiga Urinária/cirurgia , Doenças da Bexiga Urinária/congênito , Doenças da Bexiga Urinária/patologia , Urografia
13.
Neurology ; 68(22): 1944-6, 2007 May 29.
Artigo em Inglês | MEDLINE | ID: mdl-17536052

RESUMO

Reverse transcriptase has been detected in the serum of HIV-negative patients with amyotrophic lateral sclerosis (ALS). An ALS-like disorder in HIV-positive patients can remit with antiretroviral therapy. Using the product enhanced assay technique, we measured reverse transcriptase activity in the serum and CSF of 23 HIV-negative patients with ALS and 21 neurologic disease controls. Results for CSF were not significant, whereas reverse transcriptase was detected in 56% of ALS sera vs 19% of controls.


Assuntos
Esclerose Lateral Amiotrófica/sangue , Esclerose Lateral Amiotrófica/líquido cefalorraquidiano , DNA Polimerase Dirigida por RNA/análise , Adulto , Idoso , Esclerose Lateral Amiotrófica/tratamento farmacológico , Eletroforese das Proteínas Sanguíneas , Feminino , HIV , Inibidores da Protease de HIV/uso terapêutico , Soronegatividade para HIV , Humanos , Indinavir/uso terapêutico , Masculino , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase , Ensaios Clínicos Controlados Aleatórios como Assunto
14.
Am J Transplant ; 6(1): 214-8, 2006 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-16433778

RESUMO

Intrapyloric injection of botulinum toxin A (BoTx) successfully improved symptoms in idiopathic and diabetic gastroparesis (DGP) refractory to medical treatment. Therefore, we used it in three pancreas transplant patients done in our institution during the last 18 months. They had severe, persistent DGP despite successful pancreas transplantation. They received 100 units of BoTx during the first injection. The clinical effect became evident within 2 weeks after the treatment, and lasted for an average of 29 weeks (range 14-44 weeks). The patients' subjective evaluation showed improvement of their symptoms and quality of life following BoTx. Patients 2 and 3 had recurrent symptoms at 44 and 24 weeks, respectively, after the first injection; they required a second dose of 90 and 80 units, respectively. They are doing well at 3 months follow-up. Intrapyloric injection of BoTx is safe and efficient. It should be considered for treating residual DGP following successful pancreas transplantation.


Assuntos
Toxinas Botulínicas/uso terapêutico , Diabetes Mellitus Tipo 1/complicações , Gastroparesia/tratamento farmacológico , Transplante de Pâncreas , Adulto , Toxinas Botulínicas/administração & dosagem , Diabetes Mellitus Tipo 1/cirurgia , Endoscopia Gastrointestinal , Feminino , Gastroparesia/diagnóstico , Gastroparesia/etiologia , Humanos , Injeções , Piloro , Resultado do Tratamento
15.
Acta Radiol ; 45(4): 369-74, 2004 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15323387

RESUMO

PURPOSE: To analyze the utility of helical computed tomography (CT) in the diagnosis of suspected upper esophageal foreign bodies. MATERIAL AND METHODS: A prospective study was performed on 36 patients (26 F, 10 M, mean age 70 years) with a history of foreign body impaction. All had negative findings at indirect laryngoscopy. Radiologic assessment included unenhanced helical CT and a barium contrast study. Patients with positive findings were taken to esophagoscopy. All patients had a posterior clinical surveillance. RESULTS: Twenty patients had both normal CT and barium study and satisfactory clinical outcome. In 12 patients a foreign body was noted in the cervical esophagus by CT, barium study, and endoscopy. In one patient a fish bone was detected by CT (and not by barium) confirmed with esophagoscopy. Another patient had a fish bone esophageal perforation which was observed only by CT and confirmed at surgery. Two patients with normal barium and endoscopy presented a false-positive CT result. CONCLUSION: Barium swallow is currently the first radiologic study, but may involve a risk of aspiration and can impede a subsequent esophagoscopy. Esophagoscopy is an invasive technique with a certain risk of serious complications that can be avoided with a satisfactory radiologic assessment. CT is easy, fast, has 100% sensitivity and is therefore the first choice technique for diagnosing suspected upper esophageal foreign bodies not expected to be visible on plain radiographs.


Assuntos
Esôfago/diagnóstico por imagem , Corpos Estranhos/diagnóstico por imagem , Tomografia Computadorizada Espiral , Idoso , Sulfato de Bário , Meios de Contraste , Perfuração Esofágica/diagnóstico por imagem , Esofagoscopia , Reações Falso-Positivas , Feminino , Seguimentos , Humanos , Laringoscopia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Sensibilidade e Especificidade , Resultado do Tratamento
16.
Transplant Proc ; 35(8): 2881-4, 2003 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-14697927

RESUMO

INTRODUCTION: Randomized, placebo-controlled studies have determined that administration of basiliximab (chimeric IL-2 receptor antagonist) decreases the acute rejection rate in kidney transplantation when used in combination with cyclosporine, azathioprine, and steroids. We report our experience using basiliximab with mycophenolate mofetil, a calcineurin inhibitor, and steroids in kidney transplantation. METHODS: We retrospectively analyzed 127 patients who received their first kidney transplant between September 1, 1998, and December 30, 2000, including 59 who received basiliximab (22 living and 37 cadaveric donor recipients) and the 68 that did not receive this antibody (31 living and 37 cadaveric donor recipients). The groups were demographically comparable for risk factors such as race, peak of panel-reactive antibody, delayed graft function, donor age, and cold ischemia time. The analysis assessed serum creatinine levels, acute rejection, cytomegalovirus infection, and posttransplant lymphoproliferative disease incidence as well as patient and graft survival at 6 months. RESULTS: Serum creatinine levels were 3 +/- 3.1 and 2.6 +/- 2.5 mg/dL (P =.346) at discharge, 1.5 +/- 0.6 and 1.7 +/- 1.1 mg/dL (P =.098) at 1 month, and 1.5 +/- 0.7 and 1.6 +/- 0.7 mg/dL (P =.454) at 6 months posttransplantation for patients treated with versus without basiliximab, respectively. Only one episode of acute rejection was seen among patients treated with basiliximab within 1 month posttransplantation versus three episodes among patients treated without basiliximab (P =.382). Three patients (5.1%) treated with basiliximab and two patients (2.9%) treated without basiliximab developed acute rejection within 6 months posttransplantation (P =.536). Patient and graft survivals at 6 months posttransplantation were not significantly different between patients treated with versus without basiliximab (100% and 100% versus 100% and 98.3%, respectively). There was no increased incidence of cytomegalovirus infection with the use of basiliximab (5.1% vs 5.9%, P =.844). There was only one case of posttransplant lymphoproliferative disease within 6 months posttransplantation in a patient treated without basiliximab. CONCLUSION: These data suggest that the routine addition of basiliximab to a mycophenolate mofetil-based regimens does not appear to be warranted. A larger prospective randomized study with longer follow-up is needed to confirm these results.


Assuntos
Anticorpos Monoclonais/uso terapêutico , Transplante de Rim/fisiologia , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapêutico , Proteínas Recombinantes de Fusão , Adulto , Basiliximab , Cadáver , Creatinina/sangue , Quimioterapia Combinada , Feminino , Seguimentos , Humanos , Imunossupressores/uso terapêutico , Tempo de Internação , Doadores Vivos , Masculino , Prontuários Médicos , Grupos Raciais , Estudos Retrospectivos , Fatores de Tempo , Doadores de Tecidos
17.
J Fr Ophtalmol ; 26(2): 137-41, 2003 Feb.
Artigo em Francês | MEDLINE | ID: mdl-12660586

RESUMO

PURPOSE: The aim of this study was to evaluate a scoring system for chronic open-angle glaucoma. We devised an empirical scoring system grading severity of the disease and correlated this with treatment. MATERIAL: and methods: Ninety patients were evaluated on 11 parameters: 1) Family history of glaucoma: blindness (2), yes (1) no (1); 2) Age: infantile (4), juvenile (4); 3) Race: Caucasian (0), Asian (1), Afro-Caribbean (2); 4) Myopia: 0-6 diopters (1), 6-12 diopters (2),>12 diopters (3); 5) Pigment dispersion or pseudoexfoliation (1); 6) Intraocular pressure without treatment:>30 mmHg (4); 25-30 mmHg (3), 20-25 mmHg (2); 7) Corneal central thickness:<500 micro m (3),>500 micro m (0); 8) Optic disc appearance: suspect (1), pathological (4); 9) Visual field defect: early (1), moderate (3), advanced (5); 10) Vascular risk factors: yes (1), no (0); 11) Loss of eyesight in one eye due to glaucoma (4). Scoring values were 2-34. We correlated this score with patient treatment: medical or surgical, number of glaucoma medications. RESULTS: Patients were divided into three groups: group 1 (36 patients), score 0-8; group 2 (24 patients), score 9-13; group 3 (30 patients), score above 13. Distribution between patients treated with medicine (mean number of medications) and patients with filtering surgery was: group 1, medical treatment with 1.63+/-0.73 medications, surgery 4/36; group 2, medical treatment with 2.00+/-0.7 medications, surgery 17/24 and group 3, medical treatment with 2.12+/-0.67 medications, surgery 27/30. In group 1, 88% of the patients did not have filtering surgery, but 90% of the patients in group 3 had filtering surgery. CONCLUSION: This scoring system seems to be an easy and practical tool to evaluate chronic open-angle glaucoma, which could also be used to evaluate target pressure. Other studies are necessary to validate this scoring system.


Assuntos
Glaucoma de Ângulo Aberto/diagnóstico , Adolescente , Adulto , Criança , Doença Crônica , Humanos , Índice de Gravidade de Doença
18.
Pediatr Transplant ; 7(2): 137-41, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12654055

RESUMO

Mycophenolate mofetil (MMF) is a new immunosuppressive agent that blocks de novo purine synthesis in T and B lymphocytes via a potent selective inhibition of inosine monophosphate dehydrogenase. MMF has been shown to significantly reduce the incidence of acute rejection in both adult and pediatric renal transplantation. The impact of MMF on routine antibody induction therapy in pediatric renal transplantation has not been defined. Remarkably, a recent North American Pediatric Transplant Cooperative Study concluded that T-cell antibody induction therapy was deleterious for patients who received MMF. Our study examines the use of MMF in an evolving immunosuppressive strategy to avoid antibody induction in both living (LD) and cadaver (CAD) donor pediatric renal transplantation. We retrospectively analyzed the records of 43 pediatric renal transplants that received MMF-based triple therapy without antibody induction therapy between November 1996 and April 2000. We compared CAD (n = 17) with LD (n = 26). The two groups were similar demographically except that CAD had significantly younger donors than LD, 26.1 +/- 13.7 vs. 36.2 +/- 9.2 yr (p = 0.006). All the patients received MMF at 600 mg/m2/b.i.d. (maximum dose of 2 g/d) and prednisone with cyclosporine (86%) or tacrolimus (14%). Mean follow-up was >36 months for each group. Acute rejection rate at 6 months was 11.8% (CAD) vs. 15.4% (LD) (p = 0.999) and at 1 yr was 23.5% (CAD) vs. 26.9% (LD) (p = 0.999). Mean estimated glomerular filtration rate (ml/min/1.73 m2) at 6 months was 73.3 +/- 15.3 (CAD) vs. 87.6 +/- 24.2 (LD) (p = 0.068). Patient survival at 1, 2, and 3 yr was 100, 100, and 100% for CAD vs. 100, 96, and 96% for LD, respectively. Graft survival at 1, 2, and 3 yr was 100, 100, and 94% for CAD vs. 96, 88, and 71% for LD, respectively. Graft loss in CAD was because of chronic rejection (n = 2) while in LD it was because of non-compliance (n = 6), post-transplant lymphoproliferative disorder (n = 1), and sepsis (n = 1). In conclusion, MMF without antibody induction in both CAD and LD pediatric renal transplantation provides statistically similar and effective prophylaxis against acute rejection at 6 months and 1 yr post-transplant. The short-term patient and graft survival rates are excellent, however, non-compliance remains a serious challenge to long-term graft survival. Additional controlled studies are needed to define the role of MMF without antibody induction therapy in pediatric renal transplantation.


Assuntos
Imunossupressores/uso terapêutico , Transplante de Rim , Ácido Micofenólico/uso terapêutico , Adolescente , Cadáver , Distribuição de Qui-Quadrado , Criança , Ciclosporina/uso terapêutico , Quimioterapia Combinada , Sobrevivência de Enxerto , Humanos , Doadores Vivos , Ácido Micofenólico/análogos & derivados , Prednisona/uso terapêutico , Estudos Retrospectivos , Análise de Sobrevida , Tacrolimo/uso terapêutico , Resultado do Tratamento
19.
Neurology ; 57(9): 1561-5, 2001 Nov 13.
Artigo em Inglês | MEDLINE | ID: mdl-11706091

RESUMO

OBJECTIVE: To determine whether amyloid-beta protein (Abeta) can induce the production of proinflammatory cytokines by cultured normal muscle cells. BACKGROUND: Sporadic inclusion body myositis (IBM) is characterized by the presence of rimmed vacuoles and fibrillary inclusions of Abeta in muscle fibers, and often inflammatory cells. Endomysial expression of proinflammatory molecules has suggested an ongoing immune process, but the site of sensitization and the mechanisms that trigger an inflammatory reaction is unknown. METHOD: The authors used Northern blot analysis and specific immunoassays to study the expression and secretion in cell-free supernatants of tumor necrosis factor-alpha (TNFalpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) by purified human myoblasts and C2C12 mouse skeletal muscle cells incubated with Abeta[1-42] or Abeta[25-35] peptides. RESULTS: Nonstimulated muscle cells produced detectable IL-6, whereas secretion of IL-1beta and TNFalpha was absent. Incubation with Abeta peptides increased IL-6 production, whereas TNFalpha and IL-1beta levels remained undetectable. Northern blot analysis of Abeta-stimulated human myoblasts revealed an increase in IL-6 mRNA expression. CONCLUSIONS: Cultured muscle cells increase the constitutive production of IL-6 in response to local deposition of Abeta in sporadic IBM. IL-6 could be a CD8(+) proliferation and differentiation agent, an autocrine proteolysis-inducing factor of damaged myotubes, and a proliferation-stimulating agent for satellite cells to replace the destroyed myofibers in IBM.


Assuntos
Peptídeos beta-Amiloides/farmacologia , Interleucina-6/genética , Fibras Musculares Esqueléticas/imunologia , Miosite de Corpos de Inclusão/etiologia , Fragmentos de Peptídeos/farmacologia , Adulto , Animais , Células Cultivadas , Relação Dose-Resposta a Droga , Expressão Gênica/efeitos dos fármacos , Expressão Gênica/imunologia , Humanos , Interleucina-1/genética , Camundongos , Fibras Musculares Esqueléticas/citologia , Músculo Esquelético/citologia , Miosite de Corpos de Inclusão/imunologia , RNA Mensageiro/análise , Regeneração/imunologia , Fator de Necrose Tumoral alfa/genética
20.
Arch Esp Urol ; 54(5): 441-4, 2001 Jun.
Artigo em Espanhol | MEDLINE | ID: mdl-11494717

RESUMO

OBJECTIVE: To analyze the role of transrectal ultrasound in the diagnosis of diverticula of the female urethra. METHODS/RESULTS: Transrectal ultrasound assessment was performed with a biplanar 5 MHz probe and translabial ultrasound was performed with a 7 MHz linear or 3.5 MHz sectorial transducer in 9 women suspected to have urethral diverticula. Cystourethrography was also performed in three patients. Eleven diverticula were found in these 9 patients. CONCLUSIONS: The incidence of diverticula of the female urethra has been reported to range from 0.5-6%. Diagnosis is confirmed by urethroscopy or imaging methods. Transrectal ultrasound is the method of choice in the assessment of urethral diverticulum.


Assuntos
Divertículo/diagnóstico por imagem , Doenças Uretrais/diagnóstico por imagem , Feminino , Humanos , Reto , Ultrassonografia/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA